BeOne Medicines Ltd.
ONCNasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B | $308.9M |
| Operating income | $447.1M | −$568.2M | −$1.21B | −$1.79B | −$1.44B | −$1.66B |
| Net income | $286.9M | −$644.8M | −$881.7M | −$2.00B | −$1.46B | −$1.62B |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.54B | $5.60B |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | $2.40B | $1.73B |
| Equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.13B | $3.87B |
| EPS (diluted) | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 |
| Shares out. | 1.39B | 1.36B | 1.36B | 1.33B | 1.19B | 1.01B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 8.4%
- Net margin
- 5.4%
- Return on equity
- 6.6%
- Return on assets
- 3.5%
- Return on capital (ROCE)
- 7.0%
- Liabilities / assets
- 46.7%
- Debt / equity
- 0.88×
- Book value / share
- $3.14
- Revenue growth (YoY)
- 40.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.78grey zone
- Accruals / assets
- −10.3%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 5 good- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-05A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
- Phase 3Active Not Recruitingreadout ~2026-07Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- Phase 2Active Not Recruitingreadout ~2026-09-22A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
- Phase 1Not Yet Recruitingreadout ~2026-09-30A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
- Phase 1/2Recruitingreadout ~2026-11A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Phase 1/2Recruitingreadout ~2026-11A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase 2Active Not Recruitingreadout ~2026-11A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Phase 1Active Not Recruitingreadout ~2026-12-01A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Capital International InvestorsPassive (13G)May 14, 2026
- Baker Bros. Advisors LpActivist (13D)Apr 16, 2026
- Hhlr Advisors, Ltd.Activist (13D)May 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Riva AlessandroDirector | May 22, 2026 | Sell | 212 | $309.51 |
| Dugan MargaretDirector | May 22, 2026 | Sell | 212 | $309.60 |
| Sanders Corazon (Corsee) D.Director | May 22, 2026 | Sell | 212 | $309.59 |
| Baker Bros. Advisors LpDirector | May 22, 2026 | Sell | 2,743 | $23.85 |
| Lee Chan HenryOfficer — SVP, General Counsel | May 13, 2026 | Option exercise | 101 | $194.47 |
| Lee Chan HenryOfficer — SVP, General Counsel | Apr 8, 2026 | Option exercise | 101 | $194.47 |
| Lee Chan HenryOfficer — SVP, General Counsel | Mar 11, 2026 | Option exercise | 110 | $194.47 |
| Oyler JohnOfficer — Chief Executive Officer | Mar 6, 2026 | Grant | 326,976 | $0.00 |
| Lee Chan HenryOfficer — SVP, General Counsel | Mar 6, 2026 | Grant | 65,390 | $0.00 |
| Wang LaiOfficer — President, Global Head of R&D | Mar 6, 2026 | Grant | 112,606 | $0.00 |
| Wu XiaobinOfficer — President and COO | Mar 6, 2026 | Grant | 168,922 | $0.00 |
| Rosenberg AaronOfficer — Chief Financial Officer | Mar 6, 2026 | Grant | 79,014 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.0M | 4.2 | -5.8% |
| Apr 30, 2026 | 1.1M | 5.8 | -3.7% |
| Apr 15, 2026 | 1.2M | 5.3 | -5.0% |
| Mar 31, 2026 | 1.2M | 5.9 | -19.5% |
| Mar 13, 2026 | 1.5M | 5.2 | +1.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 15, 2026
- Results of operationsMay 6, 2026
- Results of operationsApr 14, 2026
- Results of operationsFeb 26, 2026
- Terminated a material agreementDec 19, 2025
- Director / officer changeDec 18, 2025
- Entered a material agreement · New financial obligationNov 19, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.